The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Avdeev S.N.

Sechenov First Moscow State Medical University (Sechenov University);
Pulmonology Scientific Research Institute, Federal Medical and Biological Agency of Russia

Leshchenko I.V.

Ural State Medical University of the Ministry of Health of the Russian Federation;
Ural Research Institute of Phthisiopulmonology — Branch of the Federal State Budgetary Institution “National Medical Research Center for Phthisiopulmonology and Infectious Diseases” of the Ministry of Health of the Russian Federation Federation;
Clinic of the Medical Association “New Hospital” LLC

Boldina M.V.

Privolzhskiy Federal Research Medical University Healthcare Ministry of Russian Federation

Van’kova E.I.

State Autonomous Healthcare Institution “Clinical Hospital No.2 of Kazan”

Demko I.V.

V.F. Voino-Yasenetsky Krasnoyarsk State Medical University

Kozyreva L.S.

Bashkir State Medical University

Korshunova L.V.

Ryazan State Medical University named after academician I.P. Pavlov

Kudelya L.M.

Novosibirsk State Medical University

Kuzubova N.A.

Federal State Budgetary Educational Institution of Higher Education First St. Petersburg Pavlov State Medical University Ministry of Health of the Russian Federation

Man L.V.

Clinical and diagnostic center “Health” in Rostov-on-Don

Mordyk A.V.

Federal State Funded Educational Institution for Higher Education Omsk State Medical University of the Ministry of Public Health of the Russian Federation

Ponomareva N.D.

State Autonomous Healthcare Institution of Sverdlovsk Region «Sverdlovsk Regional Clinical Hospital 1»

Svirido D.A.

St. Petersburg State Budgetary Healthcare Institution “City Hospital No. 2

Tsoma V.V.

Volgograd State Medical University

Shulzhenko L.V.

Kuban State Medical University;
Scientific Research Institute — Ochapovsky Regional Clinical Hospital No. 1

Clinical and patient-reported outcomes of triple therapy (budesonide/glycopyrronium bromide/formoterol) in chronic obstructive pulmonary disease: results of the observational MINERVA study

Authors:

Avdeev S.N., Leshchenko I.V., Boldina M.V., Van’kova E.I., Demko I.V., Kozyreva L.S., Korshunova L.V., Kudelya L.M., Kuzubova N.A., Man L.V., Mordyk A.V., Ponomareva N.D., Svirido D.A., Tsoma V.V., Shulzhenko L.V.

More about the authors

Journal: Journal of Respiratory Medicine. 2025;1(3): 19‑26

DOI: 10.17116/respmed2025103119

Read: 221 times

Download PDF (RU)
Contact the author
Table of contents

CLINICAL AND PATIENT-REPORTED OUTCOMES OF TRIPLE THERAPY (BUDESONIDE/GLYCOPYRRONIUM BROMIDE/FORMOTEROL) IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE: RESULTS OF THE OBSERVATIONAL MINERVA STUDY
CLINICAL AND PATIENT-REPORTED OUTCOMES OF TRIPLE THERAPY (BUDESONIDE/GLYCOPYRRONIUM BROMIDE/FORMOTEROL) IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE: RESULTS OF THE OBSERVATIONAL MINERVA STUDY

To cite this article:

Avdeev SN, Leshchenko IV, Boldina MV, et al. . Clinical and patient-reported outcomes of triple therapy (budesonide/glycopyrronium bromide/formoterol) in chronic obstructive pulmonary disease: results of the observational MINERVA study. Journal of Respiratory Medicine. 2025;1(3):19‑26. (In Russ.)
https://doi.org/10.17116/respmed2025103119

Подписка 2026 Респираторная медицина (Journal of Respiratory Medicine)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Chro­nic obstructive pulmonary disease (COPD 2024). Clinical guidelines (short version). Journal of Respiratory Medi­cine. 2025;(2):5-16
Toba­cco smoking as a factor in the deve­lopment of COPD and pulmonary tube­rculosis. Journal of Respiratory Medi­cine. 2025;(2):45-50
Rese­rves for redu­cing exacerbations in patients with chro­nic obstructive pulmonary disease at a large indu­strial ente­rprise. Journal of Respiratory Medi­cine. 2025;(2):66-70
Prognostic factors for progression and risk chro­nic obstructive pulmonary disease adve­rse outcomes. Journal of Respiratory Medi­cine. 2025;(2):71-78
Addi­tional criteria to differentiate the chro­nic obstructive pulmonary disease exacerbation and acute deco­mpensated chro­nic heart failure. Russian Journal of Preventive Medi­cine. 2024;(11):102-107
Digi­tal technologies for outpatient mana­gement of patients with chro­nic obstructive pulmonary disease: oppo­rtunities to reduce the burden of the disease. Russian Journal of Preventive Medi­cine. 2025;(9):134-139
Abstract:

OBJECTIVE

The evaluation of clinical and patient-reported outcomes in patients with chronic obstructive pulmonary disease (COPD) treated with the triple combination of budesonide/glycopyrronium bromide/formoterol (BUD/GLY/FORM) in real-life clinical practice.

MATERIAL AND METHODS

The non-interventional MINERVA study (NCT06422676) was conducted in Russia in 2023—2024. Retrospective data were collected for a period of 12 months before the start of therapy. The prospective observation period was 24 weeks from the start of therapy.

RESULTS

The study included 200 patients, average age 64.97 years, 58.5% of patients ≥65 years and older, 87.5% of patients were male, 59% were active smokers. The average baseline CAT (COPD Assessment Test) score was 23.80. A total of 137 (68.5%) patients had moderate or severe COPD exacerbations in the previous 12 months. A total of 196 patients completed 24 weeks of treatment. The mean (95% confidence interval (CI)) change in CAR score from baseline was –8.81 (–9.85; –7.76) at week 24 and –5.63 (–6.29; –4.98) at week 12. In patients with severe exacerbations in the past year, it was –11.57 (–14.08; –9.07) and –6.22 (–7.69; –4.76), respectively; in patients with elevated baseline blood eosinophil levels, the change was –9.21 (–12.25; –6.17) and –6.21 (–8.41; –4.01), respectively. A reduction in CAT by ≥2 points by week 24 was achieved in 87% of patients (95% CI 81.53%; 91.33%). The average number of moderate exacerbations per patient decreased from 0.83 to 0.03, severe exacerbations — from 0.44 to 0.02. The therapy was characterized by high compliance, was safe and well tolerated.

CONCLUSION

The use of BUD/GLI/FORM leads to an improvement in the condition of patients with COPD and can significantly reduce the frequency of exacerbations.

Keywords:

chronic obstructive pulmonary disease
fixed triple combination
budesonide + glycopyrronium bromide + formoterol
COPD Assessment Test

Authors:

Avdeev S.N.

Sechenov First Moscow State Medical University (Sechenov University);
Pulmonology Scientific Research Institute, Federal Medical and Biological Agency of Russia

Leshchenko I.V.

Ural State Medical University of the Ministry of Health of the Russian Federation;
Ural Research Institute of Phthisiopulmonology — Branch of the Federal State Budgetary Institution “National Medical Research Center for Phthisiopulmonology and Infectious Diseases” of the Ministry of Health of the Russian Federation Federation;
Clinic of the Medical Association “New Hospital” LLC

Boldina M.V.

Privolzhskiy Federal Research Medical University Healthcare Ministry of Russian Federation

Van’kova E.I.

State Autonomous Healthcare Institution “Clinical Hospital No.2 of Kazan”

Demko I.V.

V.F. Voino-Yasenetsky Krasnoyarsk State Medical University

Kozyreva L.S.

Bashkir State Medical University

Korshunova L.V.

Ryazan State Medical University named after academician I.P. Pavlov

Kudelya L.M.

Novosibirsk State Medical University

Kuzubova N.A.

Federal State Budgetary Educational Institution of Higher Education First St. Petersburg Pavlov State Medical University Ministry of Health of the Russian Federation

Man L.V.

Clinical and diagnostic center “Health” in Rostov-on-Don

Mordyk A.V.

Federal State Funded Educational Institution for Higher Education Omsk State Medical University of the Ministry of Public Health of the Russian Federation

Ponomareva N.D.

State Autonomous Healthcare Institution of Sverdlovsk Region «Sverdlovsk Regional Clinical Hospital 1»

Svirido D.A.

St. Petersburg State Budgetary Healthcare Institution “City Hospital No. 2

Tsoma V.V.

Volgograd State Medical University

Shulzhenko L.V.

Kuban State Medical University;
Scientific Research Institute — Ochapovsky Regional Clinical Hospital No. 1

Received:

18.08.2025

Accepted:

18.09.2025

Close metadata

References:

  1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2025 Report). Accessed September 14, 2025. https://www.goldcopd.org/
  2. Chuchalin AG, Khaltaev N, Antonov NS, Galkin DV, Manakov LG, Antonini P, Murphy M, Solodovnikov AG, Bousquet J, Pereira MH, Demko IV. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J Chron Obstruct Pulmon Dis. 2014;9:963-974.  https://doi.org/10.2147/COPD.S67283
  3. Maliavin AG, Dzanaeva AV, Avxentyeva MV, Babak SL. Medical and economic analysis of the consequences of expanding the drug supply program for patients with chronic obstructive pulmonary disease in the Russian Federation. Medical technologies. Assessment and Choice. 2019;3:53-61. (In Russ.). https://doi.org/10.31556/2219-0678.2019.37.3.053-061
  4. Avdeev SN, Nikitina LYu, Merzhoeva ZM, Nuralieva GS, Gainitdinova VV, Dzhioeva ON, Shamshurina NG, Berikkhanov ZG, Kharlamova SA, Deev IA, Krokhin KA. Reality and prospects of the pulmonological care for patients with chronic obstructive pulmonary disease in the Russian Federation. RMJ. 2024;1:2-6. (In Russ.).
  5. Chuchalin AG, Avdeev SN, Aisanov ZR, Belevskiy AS, Leshchenko IV, Ovcharenko SI, Shmelev EI. Federal guidelines on diagnosis and treatment of chronic obstructive pulmonary disease. Pulmonologiya. 2022;32(3):356-392. (In Russ.). https://doi.org/10.18093/0869-0189-2022-32-3-356-392
  6. Avdeev SN, Trushenko NV. Triple therapy in chronic obstructive pulmonary disease. Russian Pulmonology. 2019;29(2):199-206. (In Russ.). https://doi.org/10.18093/0869-0189-2019-29-2-199-206
  7. Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, Trivedi R, St Rose E, Ballal S, McLaren J, Darken P, Aurivillius M, Reisner C, Dorinsky P; ETHOS Investigators. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. N Engl J Med. 2020;383(1):35-48.  https://doi.org/10.1056/NEJMoa1916046
  8. Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, Bourne E, Ballal S, Darken P, DeAngelis K, Aurivillius M, Dorinsky P, Reisner C. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747-758.  https://doi.org/10.1016/S2213-2600(18)30327-8
  9. Afroz N, Gutzwiller FS, Mackay AJ, Naujoks C, Patalano F, Kostikas K. Patient-Reported Outcomes (PROs) in COPD Clinical Trials: Trends and Gaps. Int J Chron Obstruct Pulmon Dis. 2020;15:1789-1800. https://doi.org/10.2147/COPD.S235845
  10. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648-654.  https://doi.org/10.1183/09031936.00102509
  11. Dodd JW, Hogg L, Nolan J, Jefford H, Grant A, Lord VM, Falzon C, Garrod R, Lee C, Polkey MI, Jones PW, Man WD, Hopkinson NS. The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study. Thorax. 2011;66(5):425-429.  https://doi.org/10.1136/thx.2010.156372
  12. Barnes NC, Sharma R, Lettis S, Calverley PM. Blood eosinophils in COPD: a biomarker of ICS response. Lancet Respiratory Medicine. 2018;6(2):117-126. 
  13. Muro S, Hozawa S, Sugiura H, Yoshida Y, Makita N, Kato Y, Hirai T, Nishida K, Kawayama T. Real-world effectiveness of budesonide/glycopyrronium/formoterol fumarate metered dose inhaler on symptoms and quality of life in patients with COPD: EBISU study. Respir Investig. 2025;63(5):726-733.  https://doi.org/10.1016/j.resinv.2025.05.007
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.